Products and Services
Key advantages
Cooperation Partners
News
_GuweMAnr.jpg)
This symposium features Prof. Majid E. Warkiani, a globally renowned microfluidics expert and Chief Technology Officer of Labyrinth, as the keynote speaker. He will highlight the revolutionary applications of "Label-Free Viable Rare Tumor Cell Microfluidic Technology" in rare cell isolation, precision oncology, stem cell therapy, and in vitro fertilization.
July 18, 2025 – Labyrinth, in collaboration with Peking Union Medical College Hospital, has been granted a Chinese invention patent (No. ZL2025 1 0480497.X) for its "Human PDAC Ascites-Derived Tumor Cell Line and Applications".
2025-08-02
Recently, Professor Yu Hanry, a distinguished tenured professor at the National University of Singapore (NUS) and an internationally acclaimed expert in biomedical imaging and precision medicine, visited Suzhou Labyrinth Biotech Co.,Ltd.
2025-07-15
From Stanford Professor to Terminal Patient: A Doctor's Dual Journey Exposes Lung Cancer's Racial Disparities
2025-06-13
Recently, in collaboration with Peking Union Medical College Hospital (PUMCH) - specifically Professor Rui Chen's team from the Clinical Pharmacology Research Center and Professor Jiaxin Yang's team from the Gynecological Oncology Clinical Research Center - we published a landmark study titled "Human malignant ovarian germ cell tumor cell lines derived from peritoneal cytology retrieving from circulating tumor cell system" in the international journal Cancer Treatment and Research Communications.
Contact Us
0512-66033228
info@labyrinthbiotech.com
5th Floor, Building 2, No. 21 Jingu Road, Suzhou Industrial Park
_LsZ4sMEB.png)
_dMgujf0d.png)
_jpPErO0A.png)
